Janssen Pharmaceutica Nv

Amgen Inc.

Frank Chavez

Brad M Savall

James Patrick Edwards

Ronald L Wolin

Thomas T Nguyen

Jianmei Wei

Robert Michael Rzasa

Shannon Rumfelt

Essa Hu Harrington

Cheryl A Grice

Andrew Stewart Tasker

Ning Chen

Jennifer Rebecca Allen

Holger Monenschein

Bin Wu

Anthony B Reed

Matthew R Kaller

Victor J Cee

Liping H Pettus

Michael J Frohn

Steven P Meduna

Brian Alan Lanman

Laurent Gomez

Alexander J Pickrell

Ryan Paul Wurz

Hui-Ling Wang

Paul E Harrington

Hui Cai

James Richard Falsey

Andreas Reichelt

Michael P Curtis

Kaustav Biswas

Kevin L Tays

Kelvin C Sham

Roxanne Kay Kunz

Robin L Thurmond

Bradley J Herberich

Guomin Yao

Aaron M Kearney

Xiaohu Zhang

Frenel Fils De Morin

Claire L M Jackson

Jorge A Quiroz

Andrew J Greenspan

Paul J Dunford

Jian Jeffrey Chen

Jennifer Diane Venable

Mark Henry Norman

Neelakandha S Mani

Nuria A Tamayo

Jing Liu

Daniel B Horne

Thomas Nixey

Adrian Leonard Smith

Matthew Lee

Anne E Fitzgerald

Frenel Fils DeMorin

Biswas Kaustav

Daniel B Home

Kelvin Sham

Essa Hu

Roxanne Kunz

Alex Pickrell

Mike Frohn

Rob Rzasa

Tom Nguyen

Diamino-pyridine, pyrimidine and pyridazine compounds which may be used as Hreceptor modulators, and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

[object Object]

The invention relates to amide-containing compounds of formula (1), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer.

Amides as pim inhibitors

The invention relates to bicyclic compounds of formula (1'), and salts thereof. In some embodiments, the invention relates to inhibitors or modulators of Pim-1 and/or Pim-2, and/or Pim-3 protein kinase activity or enzyme function. In still further embodiments, the invention relates to pharmaceutical compositions comprising compounds disclosed herein, and their use in the prevention and treatment of Pim kinase related conditions and diseases, preferably cancer. 

Bicyclic compounds as Pim inhibitors

Diamino-pyridine, pyrimidine, and pyrazine modulators of the histamine H4 receptor

Pyridine and pyrimidine compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, bipolar disorder, obsessive-compulsive disorder, and the like.

Pyridine and pyrimidine derivatives as phosphodiesterase 10 inhibitors

2-Aminopyrimidine compounds are described, which are useful as Hreceptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

2-aminopyrimidine modulators of the histamine H4 receptor

Benzofuro- and benzothienopyrimidine compounds are described, which are useful as Hreceptor modulators. Such compounds may be used in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by Hreceptor activity, such as allergy, asthma, autoimmune diseases, and pruritis.

Growing community of inventors

Camarillo, CA, United States of America

Frank Chavez